We offer support with cancer drug development using 3D scaffolds. Our technology identifies targets associated to tumour aggressiveness and offers screening of NCEs (new chemical entities) on gene expression and other factors.

Development services are focused on solid cancer in:
– Breast
– Colon
– Ovarian
– Orphan

Iscaffpharma is currently researching additional cancer forms

The 3D printed scaffolds are available to partners wishing to conduct there own development either by

– Own printing of scaffold with Iscaffpharmas patented recipe
– Printed and distributed by Iscaffpharma

In a restricted number of partners Iscaffpharma will license the scaffold technology.

Iscaffpharma offers precision diagnostics enabling personalised treatment. We are also offering liquid biopsy as an additional diagnostic tool

Precision diagnostics
Personalized treatment
Liquid biopsy

• Identifying new targets, validation of targets
• Predicting NCEs effect on aggressive and recurrent cancer (Indicating effect on phase 3 endpoints)
• In vivo like model. Mimics true human environment
• Cost effective and improves relevance of preclinical screening
  • Reduced need for animal testing
  • 3D model enables large scale testing
• Increases success rate of cancer projects

Drug discovery and development is known to be a time and cost consuming effort. Iscaffpharmas patented scaffold technology will:

• Improve target and lead generation
• Improve quality for drug discovery and preclinical phase
• Reduce use of animal xenographs

Increases success rate in clinical trials due to preclinical testing in human, in-vivo, like setting. The predictive platform technology is applicable on any solid tumours

Source: http://biomedicalresearch.alliedacademies.com/events-list/drug-discovery-and-development-2018

Iscaffpharmas precision medicine offers opportunities to conduct research in Orphan cancer. We can offer testing in in-vivo like settings for targets and substances where no other methods are available.